SINOPHARM (01099) has announced the interim financial results for its medical device subsidiary for the six-month period ending June 30, 2026.

The unit recorded operating revenue of RMB 36.492 billion, reflecting a modest year-on-year increase of 0.36%. Operating profit reached RMB 599 million, down 12.34% compared to the same period last year. Comprehensive income attributable to the parent company's shareholders totaled RMB 287 million, a decrease of 2.56% from the prior year.